A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

Katja Weisel, Pieter Sonneveld, Andrew Spencer, Meral Beksac, Maria Rizzo, Yingxin Xu, Kyle Fahrbach, Maren Gaudig, Mary Slavcev, Lindsay Dearden, Annette Lam

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)–based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.

Original languageEnglish
Pages (from-to)151–162
Number of pages12
JournalLeukemia and Lymphoma
Volume60
Issue number19
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Multiple myeloma
  • network meta-analysis
  • systematic review

Cite this

Weisel, Katja ; Sonneveld, Pieter ; Spencer, Andrew ; Beksac, Meral ; Rizzo, Maria ; Xu, Yingxin ; Fahrbach, Kyle ; Gaudig, Maren ; Slavcev, Mary ; Dearden, Lindsay ; Lam, Annette. / A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma : a network meta-analysis. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 19. pp. 151–162.
@article{326df9aea71a4db794b0421fb65ff135,
title = "A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis",
abstract = "Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)–based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.",
keywords = "Multiple myeloma, network meta-analysis, systematic review",
author = "Katja Weisel and Pieter Sonneveld and Andrew Spencer and Meral Beksac and Maria Rizzo and Yingxin Xu and Kyle Fahrbach and Maren Gaudig and Mary Slavcev and Lindsay Dearden and Annette Lam",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1466392",
language = "English",
volume = "60",
pages = "151–162",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "19",

}

Weisel, K, Sonneveld, P, Spencer, A, Beksac, M, Rizzo, M, Xu, Y, Fahrbach, K, Gaudig, M, Slavcev, M, Dearden, L & Lam, A 2019, 'A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis' Leukemia and Lymphoma, vol. 60, no. 19, pp. 151–162. https://doi.org/10.1080/10428194.2018.1466392

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma : a network meta-analysis. / Weisel, Katja; Sonneveld, Pieter; Spencer, Andrew; Beksac, Meral; Rizzo, Maria; Xu, Yingxin; Fahrbach, Kyle; Gaudig, Maren; Slavcev, Mary; Dearden, Lindsay; Lam, Annette.

In: Leukemia and Lymphoma, Vol. 60, No. 19, 01.01.2019, p. 151–162.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma

T2 - a network meta-analysis

AU - Weisel, Katja

AU - Sonneveld, Pieter

AU - Spencer, Andrew

AU - Beksac, Meral

AU - Rizzo, Maria

AU - Xu, Yingxin

AU - Fahrbach, Kyle

AU - Gaudig, Maren

AU - Slavcev, Mary

AU - Dearden, Lindsay

AU - Lam, Annette

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)–based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.

AB - Treatment history influences the outcomes of subsequent therapies in patients with relapsed or refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment to use next. To assess the relative merits of immunomodulatory (IMiD)-free treatments, a systematic literature review (SLR) was conducted to identify relevant randomized controlled trials in patients with RRMM. A network meta-analysis (NMA) was performed to assess various IMiD-free regimens, including bortezomib and dexamethasone (Vd)–based treatments, and to explore differences in patient outcomes. The SLR identified 52 articles, from which four trials were ultimately included in the base-case NMA. The NMA showed that daratumumab plus Vd (DVd) provided a significant advantage in prolonging progression-free survival. Similar trends were observed for overall survival and overall response. Across all outcomes, DVd had the highest probability of being the best treatment. These findings suggest that DVd may provide superior clinical outcomes for RRMM patients suitable for IMiD-free regimens.

KW - Multiple myeloma

KW - network meta-analysis

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85057326226&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1466392

DO - 10.1080/10428194.2018.1466392

M3 - Article

VL - 60

SP - 151

EP - 162

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 19

ER -